Skip to main content
Home

Main navigation

  • About HIPRA

      About HIPRA

    • Scopri HIPRA
    • Storia
    • Sostenibilità e CSR
    • HIPRA nel mondo
  • Salute Animale

      Salute Animale

    • I nostri prodotti
      • Vaccini
      • Kit di diagnosi
      • Prodotti farmacologici
    • I nostri servizi
      • A proposito di Smart Vaccination
      • HIPRASTATS
      • HIPRA Diagnos
      • HIPRA University
      • Strumenti online
    • Conoscenze
    • Notizie
    • Lösungen für
      • Suini
      • Avicoli
      • Bovini
      • Ovini e caprini
      • Conigli
      • Pesci
      • Canini
  • Salute delle persone

      Salute delle persone

    • I nostri prodotti
      • COVID-19
      • Salute digestiva (GoodGut)
    • Progetti R&S
    • Notizie
    • Stampa
  • Lavora con noi
  • Contattaci
Career
Search
Search

Stampa

who we are
Stampa
01/17/2023 - 14:29

HIPRA’s COVID-19 vaccine trial in people with immunocompromising conditions was launched in Turkey

Umano
Esplora
11/07/2022 - 17:20

HIPRA starts a clinical trial to study its vaccine against COVID-19 as a 4th dose

Umano
Esplora
07/19/2022 - 10:14

HIPRA’s COVID-19 vaccine induces a good neutralising antibody response against the BA.2, BA.4 and BA.5 subvariants of Omicron

Umano
Esplora
05/18/2022 - 10:13

HIPRA initiates the first Phase III clinical trial of Covid-19 vaccine in immunocompromised people

Umano
Esplora
03/29/2022 - 14:02

EMA starts rolling review of Covid-19 HIPRA’s vaccine

Umano
Esplora
03/16/2022 - 08:45

GoodGut and Vall d'Hebron Barcelona Hospital are studying the implementation of the first non-invasive diagnostic test to detect Irritable Bowel Syndrome

Umano
Esplora
  • Load More
Home

Footer second

  • About HIPRA
  • Salute Animale
  • Salute delle persone

Footer third

  • Lavora con noi
  • Contattaci

Footer fourth

  • LinkedIn
  • YouTube

Footer

  • Termini d'uso
  • Informativa sulla privacy
  • Informativa sui cookie